MedTrace Logo

A Phase III Clinical Study of KW-2246

NCT00683995 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2020-08-28

No results posted yet for this study

Summary

This study is designed to assess the safety and efficacy of long-term KW-2246 treatment as rescue medication for breakthrough pain.

Conditions

  • Pain, Cancer

Interventions

DRUG

KW-2246 (fentanyl citrate)

KW-2246 (fentanyl citrate)

Sponsors & Collaborators

  • Kyowa Kirin Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Study Director · Kyowa Kirin Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-07-31
Completion
2011-10-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00683995 on ClinicalTrials.gov